Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
DK1-H82F5 | Human | Biotinylated Human Dkk-1 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
DK1-H5258 | Human | Human Dkk-1 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
DK1-M52H6 | Mouse | Mouse Dkk-1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DK1-H5286 | Human | Human Dkk-1 Protein, Strep Tag | ![]() |
![]() ![]() |
![]() ![]() |
DK1-H5221 | Human | Human Dkk-1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Mouse Dkk-1, His Tag (Cat. No. DK1-M52H6) at 5 μg/mL (100 μL/well) can bind Human LRP-5, Mouse IgG2a Fc Tag (Cat. No. LR5-H5254) with a linear range of 0.01-0.313 μg/mL (QC tested).
The purity of Human Dkk-1, Fc Tag(Cat. No. DK1-H5258) is more than 90% and the molecular weight of this protein is around 118-145 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BHQ-880 | BHQ-880; MOR-4910 | Phase 2 Clinical | Novartis Pharma Ag, Morphosys | Renal Insufficiency; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
Sirexatamab | DKN-01; LY-2812176 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Carcinosarcoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
This web search service is supported by Google Inc.